Sequella

Sequella receives $2.3M NIH grant for the development of tuberculosis antibiotic drug SQ641

Sequella has received a $2.3 million NIH grant to develop SQ641, a promising new TB drug that demonstrates superior in vitro activity against Mycobacterium tuberculosis. The Phase 2 SBIR grant will fund critical path studies for delivery optimization and IND-related activities.

SourceSequella·DateSep 25, 2008

Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB

SQ109 shows excellent in vitro and in vivo activity against drug-susceptible and drug-resistant TB bacteria. The treatment also synergizes with other TB drugs in experimental animal models, offering new combinations with greater activity than current standard care.

SourceSequella·DateOct 22, 2007